The BET protein family contains 4 proteins with bromodomains. These proteins are known to play role in certain cancers. Inhibiting these proteins could therefore be a cancer treatment, however, these proteins are very similar in structure but not purpose. Therefore, developing an inhibitor with enough selectivity to target the necessary protein without causing side-effects is difficult. These 4 proteins all have 2 bromodomains (BDs). The cyclic peptide in this model is noteworthy in that it only selects for BD-1. This model shows 3.1C interacting with BRD3-BD1 to inhibit it, but it should be noted that 3.1C is selective for but not among BD1s. Recent research suggests that BET-BD1 inhibitors will be most useful in combatting haematological cancers (https://doi.org/10.1016/j.ejmech.2021.113853)(https://www.pnas.org/cgi/doi/10.1073/pnas.2003086117).
Comments